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ABSTRACT 
The congenital myopathies include a wide spectrum of clinically, histologically and 
genetically variable neuromuscular disorders many of which are cause by mutations in genes 
for sarcomeric proteins.  Some congenital myopathy patients have a hypercontractile 
phenotype.  Recent functional studies demonstrated that ACTA1 K326N and TPM2 ∆K7 
mutations were associated with hypercontractility that could be explained by increased 
myofibrillar Ca
2+
-sensitivity.  A recent structure of the complex of actin and tropomyosin in 
the relaxed state showed that both these mutations are located in the actin-tropomyosin 
interface.  Tropomyosin is an elongated molecule with a 7-fold repeated motif of around 40 
amino acids corresponding to the 7 actin monomers it interacts with.  Actin binds to 
tropomyosin electrostatically at two points, through Asp25 and through a cluster of amino 
acids that includes Lys326, mutated in the gain of function mutation.  Asp25 interacts with 
tropomyosin K6, next to K7 that was mutated in the other gain of function mutation.  We 
identified 4 tropomyosin motifs interacting with Asp25  (K6-K7, K48-K49, R90-R91, and 
R167-K168) and three E-E/D-K/R motifs interacting with Lys326 (E139, E181 and E218) 
and we predicted that the known skeletal myopathy mutations ∆K7, ∆K49, R91G, ∆E139, 
K168E and E181K would cause a gain of function.  Tests by in vitro motility assay confirmed 
that these mutations increased Ca
2+
-sensitivity, whilst mutations not in these motifs (R167H, 
R244G) decreased Ca
2+
-sensitivity.  The work reported here explains the molecular 
mechanism for 6 out of 49 known disease-causing mutations in the TPM2 and TPM3 genes, 
derived from structural data of the actin-tropomyosin interface.  
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INTRODUCTION 
The congenital myopathies include a wide spectrum of clinically, histologically and 
genetically variable neuromuscular disorders, many of them caused by mutations in genes for 
sarcomeric proteins (1). These myopathies are generally defined on the basis of muscle 
weakness and histological abnormalities in the muscle fibres.  Nemaline myopathy, 
characterized by nemaline (rod) bodies on muscle biopsy, is the most widely studied but 
congenital myopathy can also be associated with cap-like structures located under the 
sarcolemma (Cap disease) or with fibre-type disproportion (CFTD).  Mutations in the skeletal 
muscle α-actin gene (ACTA1) account for about 20% of congenital myopathies and over 200 
different mutations have been identified.  Recently, disease-causing mutations have also been 
found in β- and γ- tropomyosins encoded by TPM2 and TPM3 genes respectively; 27 
mutations have been reported in the TPM2 gene and 22 mutations have been reported in the 
TPM3 gene (1-14) see supplementary figures.   
A small proportion of congenital myopathies are associated with a hypercontractile 
phenotype; this is a very heterogeneous disease category that includes distal arthrogryposis, 
trismus-pseudocamptodactyly syndrome and Escobar syndrome and some of these cases are 
reported to be due to mutations in ACTA1, TPM2 or TPM3 (12- 16).  These apparent “gain of 
function” mutations are particularly interesting because of their parallels with hypertrophic 
cardiomyopathy that also presents as a hypercontractile phenotype and is associated with 
mutations in sarcomeric proteins including  actin and tropomyosin (ACTC and TPM1 genes 
(17)).  Enhanced contractility indicates that the abnormality caused by the mutation is likely 
to be within the force-producing contractile machinery, whereas a loss of function could be 
due to defects in force production, force transmission, force sensing or sarcomere assembly. 
Tropomyosin, together with actin and troponin, constitutes the basic thin filament structural 
and Ca
2+
-regulatory machinery that interacts with myosin when muscle contracts.  
Tropomyosin forms a 40 nm long parallel coiled-coil dimer and is able to polymerise head-to-
tail with other tropomyosin molecules into long strands spanning the whole thin filament 
length.  Each tropomyosin molecule binds to 7 different actin monomers along the helical 
actin chain involving 7 quasi-repeats of about 40 amino acids each.  The key function of 
tropomyosin is in cooperatively switching the location of the actin-tropomyosin interface 
between active and relaxed states under the control of troponin, Ca
2+
 and myosin heads.
.
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Previously, we studied the effect of actin and tropomyosin mutations on Ca
2+ 
regulation of 
muscle contractility at the single filament level in order to establish a genotype-phenotype 
relationship.  In most biopsies from patients with ACTA1 mutations it was not possible to 
establish any mechanism (18-20) but two mutations are of particular note, since they showed 
distinctive abnormalities in their regulatory interaction with tropomyosin.  The ACTA1 
D292V mutation resulted in an actin with normal activity that was irreversibly switched off 
by tropomyosin (19), whilst the ACTA1 K326N mutation from a patient with stiff muscles, 
was indistinguishable from wild-type actin on its own but, when incorporated into thin 
filaments, showed an increase in Ca
2+
-sensitivity and crossbridge turnover rate consistent with 
the hypercontractile phenotype (21). 
Since tropomyosin has a relatively simple structure and interacts only with itself, actin, 
tropomodulin and troponin, we expected that it would be easier to make a molecular 
explanation of the disease phenotype than for actin mutations.  Most of the tropomyosin 
mutations reported to date are linked to different skeletal muscle myopathies characterized by 
generalised muscle weakness and, at the molecular level, a reduced cross-bridge cycling rate 
and Ca
2+
-sensitivity.  Examples of these mutations on β-tropomyosin are E41K and E117K 
linked to nemaline myopathy or cap disease (11, 22).   
Some tropomyosin mutations have been associated with arthrogryposis and a gain of function 
(15).  TPM2 R91G was the first investigated at the molecular level and this showed a 
hypercontractile phenotype (23).  Recently we have investigated in detail a common β-
tropomyosin mutation, ∆K7 that has been described in a total of 9 families (13, 24).  
Histological inspection of biopsies taken from patients of all families showed nemaline bodies 
as a common feature. Most of the patients were therefore diagnosed with nemaline myopathy, 
although some were independently diagnosed with core-rod myopathy or distal arthrogryposis 
VII.  Lysine 7 is placed in a region of crucial importance for tropomyosin, as it participates in 
the head-to-tail polymerisation of tropomyosin (25), is close to a residue binding to actin (26) 
and may also be involved in the binding of troponin T (27).  Mokbel et al. showed that the 
mutation strongly impairs the ability of the protein to incorporate in the sarcomere and causes 
its accumulation in the nemaline bodies in transfected C2C cells.  Nevertheless, the expressed 
mutant is incorporated into muscle thin filaments and it acts as a poison peptide in vivo.  
Studies with chemically skinned muscle from patient biopsies and isolated thin filaments 
using in vitro motility assay showed that this mutation increases the Ca
2+
-sensitivity, the 
cross-bridge turnover rate and maximum force, producing a gain-of-function.  In retrospect it 
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was noted that all the patients with this mutation presented a hypercontractile phenotype in 
childhood.  Distal arthrogryposis, exhibited by some of the patients, is characterised by 
hypercontraction and most of the ∆K7 patients did not present evident myopathic symptoms 
until their teens, proving that their weak muscles were not congenital. 
Recently a high resolution structure of α-tropomyosin bound to actin has been proposed, from 
a study involving electron microscopy and computational chemistry (26), that highlights the 
electrostatic interactions holding tropomyosin on F-actin.  In this structure (corresponding to 
the Closed-state, roughly equivalent to the ‘off’ functional state(28)) tropomyosin blocks 
myosin's strong binding in accord with the well known observation that skeletal muscle 
tropomyosin on its own inhibits actin-activation of myosin ATPase.  This structure provides 
the framework for understanding how the mutation could cause the gain of function. 
In this manuscript we have examined the location of tropomyosin and actin mutations in the 
new structure of the actin-tropomyosin interface.  The K7 residue is positioned just on the 
side of the K6 residue, which binds to Asp25 on the actin molecule, therefore we can propose 
that the mutation ∆K7 destabilises this inhibitory interaction.  
Moreover, since tropomyosin is a modular protein, these binding motifs are repeated in some 
of the other actin-binding repeats, thus the structure gives us a unique opportunity to predict 
where other mutations might cause a similar phenotype.  We found that four out of the seven 
quasi-repeats, present in all tropomyosin isoforms, share the feature of a second basic residue 
downstream of the basic residue binding to Asp25: K6-K7, K48-K49, R90-R91, R167-K168.  
It is interesting to note that, mutations linked to skeletal muscle myopathies have been 
reported in all four downstream basic amino acids: ∆K7, ∆K49 and R91G on β-tropomyosin 
and K168E on γ-tropomyosin and thus we predict they will cause a gain of function like ∆K7.  
A second actin-tropomyosin interface involves Lys326 of actin, the amino acids mutated in 
the ‘stiff’ patient and, interestingly, mutations have been reported in the acidic amino acids of 
tropomyosin (∆E139, E181K, ∆E218) that interact with actin K326 so we predict these would 
lead to the same effect as the K326N gain of function mutation.  In this study we have tested 
the effect of tropomyosin mutations on the actomyosin interaction by measuring Ca
2+
-
regulation of skeletal muscle thin filaments containing skeletal myopathy-causing 
tropomyosin mutations and have confirmed the molecular phenotype predicted. 
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RESULTS 
Structural analysis of actin-tropomyosin interface predicts gain of function mutations in 
tropomyosin 
Li et al. determined the structure of  α-tropomyosin bound to actin, nevertheless tropomyosin 
isoforms are highly conserved and in fact the sequences around the actin contacts studied here 
are identical in the α-, β-, and γ-isoforms (see data supplement).  The Li et al structure shows 
that tropomyosin is not closely bound to actin and makes electrostatic contact at just two 
points on every actin; at D25 and with a cluster of basic residues, K326, K328 and R147.  
This pattern is illustrated in Figure 1.  The amino acids in tropomyosin that interact with actin 
are mapped in Figure 1B in which the sequence is divided into the seven actin-binding repeats 
proposed by McLachlan and Stewart (36), based on analysis of the amino acid sequence.  
They predicted that the alpha band sequences bound to actin when actin-tropomyosin was in 
the relaxed state.  It will be seen that the basic amino acids interacting with D25 are found at 
or near the beginning of the alpha bands and the acidic amino acids interacting with the K326, 
K328, R147 cluster occur at two places near the end of the alpha band.  In the latter case, the 
first site, 12 to17 amino acids into the alpha band showed interactions in every period of 
tropomyosin, whilst the second site, 16 to 20 amino acids into the alpha band showed 
interaction in only 6 of the 7 periods.  
Tropomyosin interaction with residue Aspartic acid 25 of actin 
We noted that the gain of function mutation ∆K7 was one amino acid down stream from K6 
that interacts with actin D25 as described above.  Figure 2A shows the interface at high 
resolution.  Our initial hypothesis was that disruption of one of a cluster of basic amino acids 
(K5, K6, K7) would perturb the actin-tropomyosin interface, destabilising this structure  but 
not have such a large effect that the mutation would be lethal.  This structure corresponds to a 
functionally relaxed state of muscle, since it is well established that skeletal muscle 
tropomyosin inhibits actin activated ATPase and this position of tropomyosin relative to actin 
is present with troponin in the absence of myosin heads (37).  Consequently destabilising the 
structure would shift the equilibrium towards the active state of actin-tropomyosin, thus 
accounting for the gain of function observed with the ∆K7 mutation.  
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The motif observed with K6 and K7 is repeated in four of the periods of tropomyosin: K6-K7, 
K48-K49, R90-R91, and R167-K168 and the structures of the interface for the four motifs is 
very similar (Fig 2 A-D).  The other three periods have a single basic amino acid that interacts 
with D25 (see Figure 1).  If our hypothesis about the mechanism of the gain of function due to 
the ∆K7 mutation is correct, we would expect charge change mutations at K49, R91 and 
K168 to also cause a gain of function.  In fact the mutation R91G in period three of TPM2 is 
known to cause a hypercontractile phenotype, distal arthrogryposis and an in vitro 
investigation of the effect of this mutation did indeed find that it cause enhanced actomyosin 
ATPase and incomplete relaxation, although Ca
2+
-sensitivity was not very different from 
wild-type (23) (Figure 2C).  A survey of the published mutations in TPM2 and TPM3 reveals 
that mutations ∆K49 (period 2) and K168E (period 5) have been identified in single patients 
(Figure 2B, 2D) (7, 38), but not associated with a hypercontractile phenotype whereas no 
mutations have been reported in the equivalent positions of periods 4, 6, and 7.  Mutations at 
the amino acid directly interacting with D25 were reported in skeletal myopathy patients:  
K128E in TPM2 and R90C, R167H and R244G in TPM3 and we would predict that these 
would have a different, perhaps opposite, effect on muscle function.  In order to test our 
hypothesis, we have determined the effect of these mutations on Ca
2+
-regulation of muscle 
thin filaments.   
Tropomyosin interaction with actin residues 326,328 and 147 
This cluster of amino acids on the surface of actin forms a second interface presenting basic 
amino acids to tropomyosin (Figure 3) with at least one of the three residues involved in 
interaction in every period of tropomyosin (Figure 1) .  The actin (ACTA1) K326N mutation 
has been found in a baby suffering from a hypercontractile phenotype characterized by 
generalised stiffness (21).  In that study, in vitro motility assay studies showed that the 
mutation was sufficient to generate an increased Ca
2+
-sensitivity that explains the 
hypercontractile phenotype.  We proposed that the loss of positive charge in the K326N 
mutant actin destabilized the inhibitory interaction with tropomyosin in the same way as the 
∆K7 TPM2 mutation.  Consequently we would expect charge change mutations in the cognate 
amino acids of tropomyosin would have a similar effect.  K326 binds to tropomyosin in 5 
tropomyosin periods and one of these involves the residue E181 (Fig 1B).  The mutation 
E181K in TPM2 was reported in two cases of distal arthrogryposis and this mutation caused 
an increase in Ca
2+
-sensitivity of force production in skinned fibres from the patient (12, 39).  
Figure 4 shows the interface between actin K326 and tropomyosin E181 as defined by the Li 
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et al structure.  Thus destabilization of this interaction by loss of charge at either the actin or 
the tropomyosin residue produces the same increase in Ca
2+-
sensitivity.  There is an EEK (or 
EDK or EER) motif in tropomyosin homologous to the Actin K326-Tm 181 interface in just 
three of the seven periods (See Fig 1).  We examined published myopathy mutations in these 
motifs in the other periods of the tropomyosin sequence and found ∆E139 and ∆E218 in 
TPM2 (Figure 4) (8, 10).  It is remarkable that there are three such motifs and three reported 
mutations whilst none have been reported at the equivalent position in other periods that do 
not have this motif.  To test the predictions we investigated whether these mutations also 
caused a gain of function in vitro.   
Actin D292 mutation 
The mutation ACTA1 D292V was found in a patient with weak muscles and congenital fibre-
type disproportion (19, 40).  In vitro studies of actin purified from this patient’s skeletal 
muscle showed a very strong molecular phenotype.  The patient sample contained about 45% 
mutant actin and with actin alone the interaction with myosin in the in vitro motility assay 
was the same as normal actin, however when tropomyosin was added, the filament motility 
appeared to be completely switched off.  Li et al’s structure provides a possible reason for this 
effect.  The acidic amino acid D292 is located on the surface of actin close to the 
K326,K328,R147 cluster (Figure 4); it does not participate in binding  but is close to 
tropomyosin.  It is possible that the acidic residue in this position may act to moderate the 
binding affinity of the K326, K328, R147 cluster so that the binding is not so tight that the 
transition of tropomyosin from OFF to ON state has a physiologically impossibly high energy 
barrier.  If so, one could hypothesise that the loss of negative charge in the D292V mutation 
would strengthen binding and stabilise the off state.  We have investigated this mutation 
further to test the hypothesis. 
Effect of mutations studied by in vitro motility assay 
Tropomyosin mutations 
We expressed wild-type β-tropomyosin and the mutations ∆K49, R91G and ∆E139 and wild-
type γ-tropomyosin and the mutations R167H, K168E and R244G in the baculovirus/sf9 
system that preserves native N-terminal acetylation.  Thin filaments were reconstituted using 
the expressed tropomyosin with rabbit skeletal muscle actin and troponin and the regulation 
of their movement over immobilised HMM was studied in the in vitro motility assay.  Thin 
filaments containing mutant tropomyosin species were fully functional in this assay.  When 
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Ca
2+
-regulation of mutant thin filaments was compared with thin filaments, containing the 
appropriate wild-type tropomyosin isoform, it was observed that all the predicted gain-of-
function mutations produced a higher Ca
2+
-sensitivity (curve shifted to the left for ∆K49, 
R91G, ∆E139 and K168E; Fig 5) and a slightly higher maximum sliding speed similar to the 
previously investigated gain of function mutations, ∆K7 and E181K (24, 39).  In contrast the 
four skeletal muscle myopathy mutations that were expected to give a hypocontractile 
phenotype showed lower Ca
2+
-sensitivity (Figure 5) and lower sliding speeds (β-tropomyosin 
E41K, E117K and γ-tropomyosin R167H and R245G; Table 1).  This also corresponds to 
previously published data on E41K and R167H contraction in biopsy samples from Ochala’s 
laboratory (22, 39).  It is interesting to note that thin filaments containing 100% or 50% 
mutant tropomyosin gave similar alterations in thin filament function (Table 1). 
ACTA1 D292V mutation 
In a previous study, the ACTA1 D292V mutation appeared to stabilise the inactive state of 
actin-tropomyosin. (19).  We investigated the properties of the D292V mutation using actin 
extracted from a patient biopsy containing the mutation.  Addition of tropomyosin caused the 
D292V actin filaments to stop moving, whilst it did not affect fraction motile and slightly 
increased the sliding speed of wild-type actin (Figure 7).  In the presence of activating 
concentrations of Ca
2+
, troponin did not re-activate the thin filaments containing D292V actin 
and tropomyosin.  We then added N-ethylmaleimide-treated myosin subfragment 1 (NEM-S-
1) to actin-tropomyosin; this modified S-1 forms rigor bonds with actin even in the presence 
of ATP, therefore a small quantity will cooperatively switch on thin filaments.  However 
NEM-S-1 was incapable of switching on D292V actin- containing filaments at double the 
concentration that switched on native thin filaments in the absence of Ca
2+
(41, 42).  An actin 
mutation, E93K, that causes thin filaments to be inhibited by tropomyosin has been observed 
before, but this mutation was reactivated by either troponin or NEM-S-1 (41).  Thus the 
D292V mutation seems to have induced a very profound change of the ON-OFF equilibrium 
towards the OFF state since neither of these treatments restored motility (Figure 7). 
DISCUSSION:   
Structure of the actin-tropomyosin interface predicts gain of function mutations in skeletal 
muscle 
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Our investigation of gain of function mutations was sparked by the observation that Lysine 
326 of actin, mutated to asparagine in the muscles of the ‘stiff’ child, was in a critical position 
in the interface between actin and tropomyosin, according to the structure of Li et al  (21, 26).  
The next observation was that, unexpectedly, the TPM2 ∆K7 mutation also caused a gain of 
function and that it was located near another critical part of the actin-tropomyosin interface 
close to Asp25 (24).  The detailed information contained in Li et al’s structure combined with 
the repeating sequence of tropomyosin enabled us to identify a total of 4 similar motifs 
interacting with Asp25 and three motifs interacting with Lys326 and we anticipated that 
charge-change mutations at these sites would also cause a gain of function.  Indeed, mutations 
at two of these sites, R91G and E181K have already been reported to cause distal 
arthrogryposis, a hypercontractile phenotype, and enhanced contractility, consistent with a 
gain of function phenotype (23, 39).  In the current study, we have investigated the effect of 
the remaining predicted gain of function mutations and confirmed that they did indeed 
increase Ca
2+
-sensitivity.  The structure-function connection that we have observed is further 
supported by our observation that charge-change mutations at positions adjacent to the 
predicted gain-of-function sites (R167H and R244G) produced the opposite effect, namely a 
reduced Ca
2+
-sensitivity. 
The finding that the Li et al structure can accurately predict seven gain of function mutations 
in tropomyosin strongly supports the validity of actin-tropomyosin interface structure on 
which it is based. 
Implications for diagnosis of skeletal muscle disease- histopathology is an inappropriate 
criterion 
Skeletal muscle myopathies are historically defined by the histopathology of the muscle; 
however, the determination of the disease-causing mutations and the advent of functional 
studies suggest a different approach to diagnosis is needed(43). 
No relationship between the conventional disease classification and the gain of function 
phenotype could be ascribed.  Amongst the 7 mutations investigated, diagnoses include cap 
myopathy, nemaline myopathy, congenital fibre-type disproportion (CFTD), rod-core disease, 
distal arthrogryposis and trismus-pseudocamptodactyly In fact, the single mutation ∆K7 
studied in 10 families included diagnoses of rod-core disease, CFTD and trismus-
pseudocamptodactyly (13, 24).  A similar range of diagnoses was given for the R167 
mutations found in 14 families where nemaline myopathy, CFTD, cap disease and mixed 
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pathologies were reported (14). 
Whilst muscle histology provides no clues about the basis of the myopathy, consideration of 
muscle contractility is more predictive, especially for the gain of function mutations.  This 
aspect was thoroughly investigated for the ∆K7 mutation, where some patients were re-
evaluated and re-diagnosed in the light of contractility measurements (24).  Besides the overt 
hypercontractility seen in arthrogryposis (E181K, R91G, ∆K7) there was a tendency for the 
gain of function patients to have contractures in infancy and abnormal gait whilst major 
symptoms of muscle disorders were delayed; for instance the ∆E139 patient was first 
examined at 11 years for a muscular-skeletal disorder (10).  A clearly hypocontractile 
phenotype from birth would rule out a gain of function type of mutation.  These features may 
not be considered in most neuromuscular clinics: it will be noted that the patients with the 
three gain of function mutations investigated here (∆K49, ∆E139 and K168E) were not 
diagnosed with a hypercontractile phenotype (10, 38, 44). 
This situation somewhat parallels hypertrophic cardiomyopathy (HCM), which is also 
associated with increased Ca
2+
-sensitivity, where symptoms frequently do not develop until 
an individuals’s second and third decades. In both cases, an initially hypercontractile 
phenotype can trigger secondary muscle dysfunction leading to a hypocontractile phenotype 
mimicking the more common loss of function mutations as discussed by Mokbel et al. for the 
∆K7 mutation (24).  In HCM, enhanced Ca
2+
-sensitivity is the primary defect that triggers 
hypertrophy but biopsies of interventricular septum from such patients invariably have a 
hypocontractile phenotype, indeed up to 30% of untreated patients subsequently develop 
symptoms of heart failure (17, 45) 
Implications for the structural analysis of tropomyosin regulation 
The control of striated muscle activity is mediated through Ca
2+
-regulation of the thin 
filament and this has been shown to be due to a series of allosteric-cooperative transitions 
between activity states involving every protein component of the thin filament and myosin, 
largely defined by the position of tropomyosin on the surface of actin (49).  Measurement of 
Ca
2+
-sensitivity is therefore a very sensitive method to detect changes in equilibria between 
states.  The Li et al structure of skeletal muscle tropomyosin on the surface of actin filaments 
indicates that, when freed of constraints imposed by troponin, myosin, or other actin-binding 
proteins, tropomyosin localizes to a favored position on F-actin defined primarily by 
electrostatic interactions that corresponds most closely to the blocked and closed states as 
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defined by Lehman et al. 2009 (26, 46).  Recent energy landscape calculations confirm that 
tropomyosin is located in a shallow energy well (28) and that the “open” conformation is 
energetically unfavoured except in the presence of strong myosin binding to actin, as 
demonstrated in the recent determination of the actin-tropomyosin-S-1 structure (47). 
It is logical to propose that the mutations in tropomyosin and actin that cause a gain of 
function by de-stabilising the actin-tropomyosin B/C-states and therefore shifting the 
equilibrium slightly in favour of the open state.  The shift in equilibrium is detected as a 
higher Ca
2+
-sensitivity since the change of activity state and Ca
2+
 switching of the thin 
filament are linked equilibria (49).  There is, in fact, direct evidence for this:  firstly the 
affinity of tropomyosin for actin is reported to be reduced in the gain of function mutations 
∆K7, ∆K49, R91G and ∆E139 (11, 23, 24) and secondly, energy landscape calculations of the 
effect of the actin K326N gain of function mutation actually show that the interaction energy 
(van der Waals + electrostatic) is reduced from 3286 to 2306 kcal/mol and the energetically 
most favoured position of tropomyosin is shifted in the direction of the open state (48).  
A similar analysis may explain why the actin D292V mutation is so profoundly inhibitory; the 
location of negative charge relative to the three basic amino acids K326, K328 and R147 may 
be crucial in defining the shallow energy minimum of tropomyosin in the C state that is 
necessary to allow the regulatory transition to the other states with minimal energy 
expenditure.  Preliminary energy landscape calculations indicate that actin-tropomyosin 
interaction energy is increased when D292 is mutated to valine from -3286 to -3442 kcal/mol 
based on the charge change alone.  The mutation of the negatively charged amino acid to a 
hydrophobic amino acid could also allow a conformational change that makes the energy well 
deeper thus trapping tropomyosin in the C-state.  
The information provided by these studies gives new insight about the structure-function 
properties at the actin-tropomyosin interface. One important implication of these results is the 
obligate requirement of charged residues in key positions to achieve normal regulation.  
It is more difficult to explain why tropomyosin mutations causing a gain of function are 
located not in the amino acid that interacts directly with actin Asp25, but in the adjacent 
amino acid.  There is no other pattern:  two are deletions, one is a charge reversal and one is a 
charge loss.  One might hypothesise that a positive charge-reducing mutation at the 
interaction site itself would have such a large effect as to be lethal and therefore not be seen 
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for that reason, however this argument fails since mutations of Arg167 to Cys, His or Gly are 
one of the commonest of skeletal myopathy-causing mutations, having been identified in 14 
families. 
Likewise there is no obvious explanation of why the gain of function mutations involved with 
interaction with Lys326 in actin are located at the amino acid in tropomyosin that interacts 
with actin. 
On a more general point, these studies indicate that when the molecular structure and function 
of a protein-protein interface is well understood it is possible to make quite precise and 
testable predictions about the effect of disease-causing mutations, especially in a repeating 
structure like tropomyosin. The work reported here suggests a molecular mechanism for just 6 
out of 49 known TPM2 and TPM3 mutations.  It is interesting to note that none of the 26 
mutations in TPM1 identified as causes of cardiomyopathy are involved in the actin binding 
motifs described here (see supplementary data), indicating a different mechanism of 
modification of function for these phenotypes.  The effect of mutations in tropomyosin and 
actin on the interface in the ‘on’ state as described by Behrman et al. (47) has not yet been 
investigated and the study of mutations in tropomyosin's interfaces with troponin and 
tropomodulin awaits further structural analysis. In the future such studies could define which 
other residues in the protein are key for optimal regulation and potentially highlight 
therapeutic targets or treatments. 
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METHODS 
Sources of contractile proteins 
Skeletal muscle myosin, heavy meromyosin, troponin and α-actin were prepared as described 
by Bing et al 1997. Tropomyosin was expressed in a baculovirus/Sf9 system and purified with 
a protocol based on that of Akkari et al.(29) as described by Memo et al. (30).  Age-matched 
normal and D292V human skeletal muscle actin was obtained from muscle biopsies as 
described by Clarke et al 2007 (19). 
Quantitative in vitro motility assay 
Thin filaments were reconstituted with 10nM rabbit skeletal muscle α-actin (labelled with 
TRITC phalloidin) (31),  tropomyosin (20-30nM) and troponin (10-30nM) to study Ca
2+
-
regulation of filament motility by the quantitative in vitro motility assay (32, 33).  Thin 
filament movement over a bed of immobilised rabbit fast skeletal muscle heavy meromyosin 
(HMM) (100 µg/ml) was compared in paired motility cells in which troponin varied by a 
single factor (mutation or phosphorylation state).  Filament movement was recorded and 
analysed as previously described (34), yielding two parameters, the fraction of filaments 
moving and the speed of moving filaments.  In our motility system both these parameters are 
regulated by Ca
2+
. The fraction motile changes from <0.1 to >0.8 in the range 1 nmol/L to 3.7 
µmol/L free Ca
2+
.  The Ca
2+
-dependent change of sliding speed was less and more variable 
(0-50% change), as previously noted Song 2010  (35). 
The fraction motile and sliding speed was measured over a range of Ca
2+
 concentrations to 
generate Ca
2+
-activation curves.  Each experiment involved the preparation of test and control 
troponins at the same time.  To keep intra-experiment variability as low as possible, test and 
control thin filaments were reconstituted together and for each Ca
2+
-concentration point they 
were pipetted into two channels of the dual chamber motility cell.  Motility was then 
measured in each chamber within a couple of minutes of each other.  The data was fitted to 
the 4-variable Hill equation to yield a value for EC50.  EC50 values from replicate experiments 
were analysed by paired t-test since the distribution of EC50 has been shown to be normal (32, 
33).  The absolute value of EC50 was slightly variable between different troponin and myosin 
preparations, but the ratio of control to test was very consistent (Table 1). 
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Molecular structures 
Structural analysis used a refined version of the structure of the actin tropomyosin interface 
published by Li et al. (26).  PDB files describing the coordinates of 15 actins and one 
tropomyosin in this structure were rendered using MacPyMol.  The pdb files are included in 
supplementary data. 
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FIGURES 
Figure 1    Structure of the actin-tropomyosin interface  
A)  Structure of one of the two tropomyosin molecules (cyan) bound to the actin double-helix 
(grey).  Surface rendering using PyMol with coordinates from Li et al (2011). Actin Asp25 is 
coloured red and Lys 326 is coloured blue.  
B) The β-tropomyosin sequence divided in the 7 quasi-repeating periods and α- and β-bands 
as defined by Mclachlan and Stewart (1976) . The purple circles highlight residues interacting 
with actin Asp25; the orange and red circles highlight the residues interacting with actin R147, 
K326 and K328 as defined by Li et al (2010). The β-tropomyosin (TPM2) mutations are 
indicated in blue boxes, the γ-tropomyosin (TPM3) mutations are in green boxes. The 
mutations increasing the Ca
2+
-sensitivity are written in red, while those decreasing it are 
written in black. 
Figure 2 Details of the interactions of tropomyosin with actin Asp25  
Magnified views of the Li et al structure from Figure 2A show the locations of proposed gain 
of function mutations in tropomyosin relative to Actin Asp 25 for the first (K6,K7), second 
(K46,K47),   third (R90,R91) and fifth (R167,K168)  periods of tropomyosin.  
Figure  3 Location of actin residues Lys326, Lys328, Arg147 and Asp272 
Magnified views of the Li et al structure from Figure 2A.  Left, actin alone is shown; right, 
tropomyosin is overlaid at 50% transparency. Amino acids are identified on the figure. The 
lower cluster is viewed face on whilst the upper cluster is rotated to the right.   
Figure 4 Details of the interactions of tropomyosin with Actin Lys326, Lys328 and 
Arg147  
Magnified views of the Li et al structure from Figure 2A show the locations of proposed gain 
of function mutations in tropomyosin relative to actin Lys326, Lys328 and Arg147 in the 
fourth (E139), fifth (E181) and sixth (E218,D219) periods. 
Figure 5 Comparison of Ca
2+ 
regulation of thin filaments containing wild-type and 
mutant tropomyosin.  
Thin filament motility was measured by in vitro motility assay over a range of [Ca
2+
] in 
paired cells.  The fraction of filaments motile is plotted as a function of [Ca
2+
] for a typical 
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experiment.  The points are the mean±SEM of four determinations of fraction motile 
measured in one motility cell.  The curves are fits of the data to the Hill equation.  Solid lines 
and points, wild-type thin filaments, dashed lines and open points, thin filaments with mutant 
tropomyosin.  The mean values of EC50 from replicate experiments is plotted in Figure 6 and 
summarised in Table 1. 
 
Figure 6 The effect of skeletal myopathy mutations in tropomyosin on thin filament 
Ca
2+
-sensitivity. 
Data from this paper and published work is combined.  Black, predicted gain of function 
mutations, white, predicted loss of function mutations. 
Ratio of EC50 of mutant thin filaments relative to EC50 of wild-type troponin-tropomyosin is 
plotted.  Error bars show SEM of up to 12 replicate comparative measurements (see table 1).  
a  -  from Mokbel et al, 2013(24) 
b – from Ochala et al 2012(39) 
c – from Marttila et al 2012 (11) 
d – from Ochala et al 2008  (22) 
 
Figure 7 The effect of the actin Asp292Val mutation on actin-tropomyosin 
interaction measured by the in vitro motility assay. 
Actin movement over immobilised HMM was recorded and analysed.  Two parameters were 
calculated: fraction of filament motile and the sliding speed of motile filaments. Rhodamine-
phalloidin labelled Actin concentration was 10nM.   Solid lines: wild-type actin, dotted lines 
D292V actin. 
A The effect of up to 30nM tropomyosin on wild-type and mutant actin motility 
B The effect of adding 50nM troponin to actin-tropomyosin at 3.6x10
-5
 M Ca
2+ 
C The effect of adding 18nM NEM S-1 to actin-tropomyosin. 
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Table 1 
The effect of tropomyosin mutations on Ca
2+
-sensitivity and maximum sliding speed in reconstituted skeletal muscle thin filaments measured by 
in vitro motility assay.  Combined data from n replicate Ca
2+
-activation curve measurements like those shown in figure 5.  The significance,p, of 
deviation of theEC50 ratio from 1 was determined by a single value t-test. 
mutation 
EC50 Mut, µM 
± SEM, n,p 
EC50 WT,µM  
± SEM, n,p 
Ratio EC50 WT/EC50 Mut 
± SEM, n,p 
Max Sliding speed relative to 
WT, µm/s 
± SEM, n,p 
∆K49    100% 0.04 ± 0.002 0.08 ± 0.01 2.42 ± 0.25, n=6, p=-.002 98.1±2.7%, n=3, p=0.555 
   50% 0.03 ± 0.002 0.09 ± 0.003 2.71 ± 0.06, n=6, p<0.0001 101.0 ± 0.6% 
R91G    100% 0.05 ± 0.01 0.09 ± 0.01 1.83 ± 0.18, n=6, p=0.006 102.2 ± 1.0%, n=3, p=0.160 
    50% 0.06 ± 0.01 0.09 ± 0.004 1.55 ± 0.05, n=6, p=0.0002 100.2 ± 0.6% 
∆E139   100% 0.03 ± 0.004 0.12 ± 0.03 2.95 ± 0.43, n=6, p=0.006 101.1 ± 2.4%, n=3, p=0.687 
     50% 0.03 ± 0.004 0.11 ± 0.01 2.58 ± 0.49, n=6, p=0.003 104.2 ± 1.1% 
R167H    100% 0.16 ± 0.02 0.07 ± 0.01 0.59 ± 0.08, n=6, p=0.004 92.5 ± 2.6%, n=3, p=0.101 
     50% 0.13 ± 0.02 0.08 ± 0.01 0.59 ± 0.01, n=2 95.0% 
K168E    100% 0.05 ± 0.01 0.08 ± 0.01 2.17 ± 0.32, n=8, p=0.008 107.2 ± 1.6% 
     50% 0.05 ± 0.003 0.09 ± 0.001 1.84 ± 0.07, n=12, p<0.0001 105.4 ± 2.7% 
R245G    100% 0.12 ± 0.02 0.05 ± 0.02 0.46 ± 0.08, n=6, p=0.001 97.1 ± 4.7%, n=3, p=0.598 
    50% 0.11 ± 0.003 0.08 ± 0.01 0.67 ± 0.07, n=2 93.6% 
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